5,0
10. Juni 2026
Mitarbeiter (anonym)
Aktueller Mitarbeiter
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Robust discovery pipeline and stable leadership team. Big biotech structure with small biotech flexibility.
Kontras
Busy schedule with early meetings. Imbalanced headcount distribution for some groups.